Skip to content
Technetium tc 99m sestamibi
Technetium tc 99m sestamibi is a small molecule pharmaceutical. Technetium tc 99m sestamibi was first approved as Technetium tc 99m sestamibi on 2008-09-22.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
kit for the preparation of technetium tc99m sestamibiANDA2020-03-31
technetium tc 99m sestamibiANDA2022-05-19
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09G: Cardiovascular system diagnostic radiopharmaceuticals
— V09GA: Technetium (99mtc) compounds
— V09GA01: Technetium (99mtc) sestamibi
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I21———123
Thyroid neoplasmsD013964EFO_0003841———1—1
Type 2 diabetes mellitusD003924EFO_0001360E11———1—1
Coronary restenosisD023903EFO_0004224———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.1—22—15
Mucocutaneous lymph node syndromeD009080EFO_0004246M30.3111——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.9011———2
Kidney neoplasmsD007680EFO_0003865C64—1——12
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Uterine cervical neoplasmsD002583—1———1
NeoplasmsD009369C80—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501———45
Molecular imagingD0570541————1
Triple negative breast neoplasmsD0647261————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial ischemiaD017202EFO_1001375I20-I25————22
Myocardial reperfusionD015425————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTECHNETIUM TC 99M SESTAMIBI
INNtechnetium (99mtc) sestamibi
Description
Technetium (99mTc) sestamibi (INN) (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
[H]/[C-]=N\CC(C)(C)OC.[H]/[C-]=N\CC(C)(C)OC.[H]/[C-]=N\CC(C)(C)OC.[H]/[C-]=N\CC(C)(C)OC.[H]/[C-]=N\CC(C)(C)OC.[H]/[C-]=N\CC(C)(C)OC.[Tc+6]
Identifiers
PDB—
CAS-ID109581-73-9
RxCUI—
ChEMBL IDCHEMBL4594241
ChEBI ID—
PubChem CID25199598
DrugBankDB09161
UNII ID971Z4W1S09 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 0 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
435 adverse events reported
View more details